<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01960478</url>
  </required_header>
  <id_info>
    <org_study_id>5476</org_study_id>
    <nct_id>NCT01960478</nct_id>
  </id_info>
  <brief_title>Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke</brief_title>
  <official_title>Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the USA, every year 795,000 patients suffer a cerebral vascular accident (CVA), which&#xD;
      represents a yearly cost of $73.7 billion. CVA is the third main cause of death and the main&#xD;
      source of acquired handicap in adults, as a result it is now a key priority in public health&#xD;
      and part of &quot; The CVA National Action Plan 2013-2014&quot;.&#xD;
&#xD;
      Copeptin is a polypeptide, by- product of Vasopressin metabolism. The increase of Copeptin&#xD;
      plasma level, as for Vasopressin, is connected to hydric balance disorders found in&#xD;
      cardio-vascular, renal and endocrine diseases. This link has already shown its interest in&#xD;
      the early diagnosis of myocardial infarction and, in a more indirect way, CVA.&#xD;
&#xD;
      Copeptin is associated with acute endogenous stress. It seems to have interesting potential&#xD;
      in the diagnosis of CVA by its negative predictive value like D-dimeres in pulmonary&#xD;
      embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the&#xD;
      prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2014</start_date>
  <completion_date type="Actual">October 5, 2014</completion_date>
  <primary_completion_date type="Actual">October 5, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the minimum level of Copeptin required to determine if the patients present with acute CVA or not.</measure>
    <time_frame>Participants will be followed during 90 days</time_frame>
    <description>Copeptin is associated with acute endogenous stress. It seems to have interesting potential in the diagnosis of CVA by its negative predictive value like D-dimers in pulmonary embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Cerebral Vascular Accident (CVA)</condition>
  <arm_group>
    <arm_group_label>bood test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>(for each intervention)</intervention_name>
    <arm_group_label>bood test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <arm_group_label>bood test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients, male or female, may be included if they meet the following criteria:&#xD;
&#xD;
          -  patients with suspected ischemic CVA admitted in an acute stroke unit (thrombolysis&#xD;
             unit).&#xD;
&#xD;
          -  aged 18 and over.&#xD;
&#xD;
          -  MRI Scan undertaken under the current protocol which includes the following sequences:&#xD;
             distribution, T2* (gradient echo), ARM, TOF and FLAIR.&#xD;
&#xD;
          -  after information given the consent form is signed:&#xD;
&#xD;
               -  by the patient .or for those unable to express their consent (in case of coma or&#xD;
                  severe neurological disorder) by a relative or next of kin.&#xD;
&#xD;
        .the patient will be informed as soon as he has recovered his faculties in order to be able&#xD;
        to express, if he wishes, his opposition to the pursuit of the research (sample destruction&#xD;
        before tested).&#xD;
&#xD;
        - the patient must be registered with the Social Security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All patients with a contraindication to MRI Scan:&#xD;
&#xD;
          -  Pacemaker,&#xD;
&#xD;
          -  Implanted cardiac defibrillator,&#xD;
&#xD;
          -  Implanted Neuro-stimulator,&#xD;
&#xD;
          -  Cochlear Implants&#xD;
&#xD;
          -  Implanted Insulin pump&#xD;
&#xD;
          -  Other implanted electronic medical device&#xD;
&#xD;
          -  Vascular intracerebral Clip&#xD;
&#xD;
          -  Cardiac Valve&#xD;
&#xD;
          -  Other metallic implant&#xD;
&#xD;
          -  Metallic foreign body&#xD;
&#xD;
          -  Ventricular diversion valve&#xD;
&#xD;
          -  Eye or hearing prosthesis&#xD;
&#xD;
          -  Current or suspected pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
        Those who are under protection of justice, under guardianship or curatorship will also be&#xD;
        excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien HARSCOAT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service des Urgences Médico-Chirugicales Adultes Hôpitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

